eligibility_summary
Eligible: advanced gastric/EGJ adenocarcinoma or pancreatic cancer, CLDN18.2 IHC+ tumor, ECOG 0–1, measurable disease, survival ≥12 wks, adequate organs, prior AEs ≤G1, contraception/consent. Exclude: pregnancy/lactation, active HIV/HBV/HCV or serious infection, uncontrolled effusions, extensive lung/liver mets, CNS disease or hepatic encephalopathy, significant cardiac disease, bleeding risk, poorly controlled HTN/T2DM, systemic steroids, allergy to IMC008, noncompliance
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: IMC008, an autologous chimeric antigen receptor T-cell (CAR-T) therapy engineered to recognize the tight junction protein Claudin 18.2 (CLDN18.2), it is NKG2D receptor–modified to enhance T-cell activation via engagement of NKG2D ligands. Mechanism of action: CAR binding to CLDN18.2 activates T-cell signaling (CD3ζ/co-stimulation), driving cytotoxic killing and cytokine release against tumor cells, NKG2D signaling may provide additional co-stimulation and recognition of MICA/B and ULBP ligands on tumors. Targets: CLDN18.2-positive tumor cells (gastric/GEJ and pancreatic cancers) and the NKG2D immune-activating pathway.